- Active not recruitingPHASE1
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
This study is testing two medicines, Naporafenib and Trametinib, together for certain advanced cancers. It's for people whose cancer has a specific change called RAS Q61X, and who haven't responded to other treatments or have limited options.
For: Advanced or Metastatic Solid TumorsUnited States · Australia · Canada - Active not recruitingPHASE3
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
This study is looking at a new combination of medicines, naporafenib and trametinib, for people with a specific type of advanced melanoma. It aims to see if this combination works better than standard treatments for patients whose melanoma has certain genetic changes and has progressed after other treatments.
For: Advanced or Metastatic NRAS-mutant MelanomaUnited States · Australia · Canada